ETS1 has been reported to be upregulated in a variety of tumors and could be considered as a prognostic marker in patients with tumors including breast cancer, ovary and cervix carcinoma and hepatocellular carcinoma [42–46]. Here, ETS1 is linked to cervical carcinoma.